- Home
- IRWD vs HUYA Comparison
IRWD vs HUYA Comparison
Compare IRWD & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IRWD | HUYA |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.6M | 572.2M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IRWD | HUYA |
|---|---|---|
| Price | $3.57 | $2.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $7.67 | $3.50 |
| AVG Volume (30 Days) | ★ 2.0M | 1.5M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 81.37% |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $57.95 | $14.08 |
| Revenue Next Year | $4.39 | $6.11 |
| P/E Ratio | $14.73 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $0.66 | $2.21 |
| 52 Week High | $5.78 | $4.93 |
Technical Indicators
Market Signals| Indicator | IRWD | HUYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 25.42 |
| Support Level | $3.08 | N/A |
| Resistance Level | $3.95 | $3.34 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 67.44 | 4.12 |
Price Performance
Historical ComparisonAbout IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.